Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems

TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.

Dengue virus vaccine

Sanofi's announcement last month that its Dengvaxia dengue vaccine may worsen the illness in vaccinated individuals who have not previously had dengue infection raised concerns about use of the vaccine. While Sanofi is advising caution in administering its product, Takeda Pharmaceutical Co. Ltd. has designed its candidate vaccine with the goal to have it be effective regardless of prior exposure.

The Pink Sheet spoke with Derek Wallace, the head of Takeda's global dengue program, about what impact the findings might...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet